The growth hormone secretagogue family is one of the most studied groups in peptide research, and one of the most frequently confused, because its members work through two entirely different receptor systems. Understanding the split is essential for designing clean studies of the somatotropic axis. This guide explains how the pituitary controls growth hormone release, how each of the two compound families plugs into that control, and why combining one from each is the classic experimental design.
How Growth Hormone Release Is Controlled
Growth hormone (GH) is made and released by somatotroph cells in the anterior pituitary, in pulses, mostly during deep sleep. Two hypothalamic hormones set the rhythm. Growth hormone-releasing hormone (GHRH), a 44-residue peptide, stimulates release; somatostatin inhibits it. The alternation between the two produces the pulses. A third signal, ghrelin, discovered in 1999 as a 28-residue hormone from the stomach, also stimulates GH release, through a receptor on the same somatotroph cells that had been known for a decade as the “growth hormone secretagogue receptor” (GHS-R) before anyone found its natural ligand. Synthetic GH secretagogues had been designed in the 1980s to activate that orphan receptor, which is why the compound family predates the hormone.
Once released, GH acts on the liver to produce insulin-like growth factor 1 (IGF-1), which mediates most of GH’s growth effects and feeds back to suppress further GH release. IGF-1 LR3 is the research tool for studying that downstream step directly (see IGF-1 LR3 in Cell Culture).
Pathway One: GHRH Receptor Analogs
The first group mimics GHRH, the hypothalamic signal that instructs pituitary somatotrophs to release growth hormone. The GHRH receptor is a class B G-protein-coupled receptor that signals through cyclic AMP. All of native GHRH’s activity lives in its first 29 residues, and the natural peptide is destroyed within minutes by DPP-4, so the members of this family differ mainly in how they achieve stability:
- Sermorelin: the 1-29 fragment of native GHRH, the shortest fully active sequence, with a naturally brief, pulsatile profile. It is the reference compound for the receptor.
- Tesamorelin: the complete 44-residue GHRH sequence stabilized with a trans-3-hexenoic acid group at the N-terminus, which protects against DPP-4 and extends activity to hours.
- CJC-1295: a modified 1-29 analog engineered for substantially longer half-life through four cleavage-resistant substitutions, available with a DAC albumin anchor (half-life of days) or without (about 30 minutes). The two forms are compared in CJC-1295 With and Without DAC.
GHRH analogs amplify the natural pulse: they increase the amount of GH released when the somatotroph is ready to release, but they do not override somatostatin, so GH stays pulsatile and under physiological feedback.
Pathway Two: Ghrelin Receptor (GHS-R) Agonists
The second group works through the growth hormone secretagogue receptor, the ghrelin receptor, a completely separate signaling route. GHS-R1a is a class A GPCR that signals through phospholipase C, raising intracellular calcium, rather than through cyclic AMP. It is expressed on somatotrophs, where it stimulates GH release and partially counteracts somatostatin, and in the hypothalamus, where it stimulates incretin-pathway and GHRH release. Members:
- Ipamorelin: a pentapeptide prized in research for selectivity, stimulating GH release with minimal influence on cortisol, prolactin, or incretin-pathway in published preclinical work. That selectivity makes it the cleanest tool for isolating GHS-R effects on the GH axis.
- GHRP-6: an earlier-generation hexapeptide, one of the original synthetic secretagogues from the 1980s, that also raises cortisol and prolactin and strongly engages ghrelin-linked incretin-pathway pathways, making it a dual-purpose research probe for GH release and feeding behavior.
The Two Pathways Compared
| GHRH analogs | Ghrelin receptor agonists | |
|---|---|---|
| Receptor | GHRH-R (class B GPCR) | GHS-R1a (class A GPCR) |
| Second messenger | Cyclic AMP | Calcium / phospholipase C |
| Effect on somatostatin | Does not override it | Partially counteracts it |
| Other effects | Minimal | incretin-pathway, cortisol/prolactin (compound-dependent) |
| Compounds | Sermorelin, Tesamorelin, CJC-1295 | Ipamorelin, GHRP-6 |
| Typical size | 29–44 residues | 5–6 residues |
Why Combination Designs Dominate the Literature
Because the two pathways converge on the same endpoint through different receptors and different second messengers, pairing one compound from each class is a classic study design for examining synergistic release. In preclinical and early human studies, a GHRH analog plus a ghrelin-receptor agonist produces a GH pulse substantially larger than the sum of the two alone, because cyclic AMP and calcium signaling reinforce each other inside the somatotroph and because the ghrelin arm relieves the somatostatin brake that limits the GHRH arm. Pre-combined research blends like CJC-1295 (No DAC) + Ipamorelin and Tesamorelin + Ipamorelin package the two mechanisms in a single vial for combination protocols, with matched lots (see Peptide Blends Explained). Single vials remain the right choice when the question is which arm is responsible for an effect.
Open Questions
- Pulse versus tone. Pulsatile and continuous GH exposure produce different gene expression in the liver and different metabolic effects; which exposure pattern a given compound produces, and whether that matters for a given endpoint, is central to interpreting results.
- Ghrelin receptor constitutive activity. GHS-R1a signals at a high basal level even without ligand, and some compounds act as inverse agonists; this complicates comparisons across ghrelin-class compounds.
- Desensitization. Long-acting GHRH analogs (the DAC form of CJC-1295) raise questions about receptor downregulation under continuous stimulation.
Handling Notes
The GHRH analogs are long peptides (29–44 residues) and more fragile in solution than the short ghrelin agonists; Tesamorelin and Sermorelin contain a methionine and should be protected from air and light. Ipamorelin and GHRP-6 are robust pentapeptides and hexapeptides, though GHRP-6 contains two tryptophans and is light-sensitive. All should be reconstituted gently in bacteriostatic water, refrigerated, and used within a few weeks; see Storing Lyophilized Peptides. A Certificate of Analysis confirming mass is the way to tell the CJC-1295 forms apart.
Sourcing for Axis Research
Our full Endocrine Signaling Research collection spans both pathways, every batch third-party verified at 99%+ purity with COA documentation.
All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.



